Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS, Haeck I, van der Gang LF, Dekkers CC, van der Rijst LP, Oosting AJ, van Lumig P, van Lynden-van Nes AMT, Tupker RA, Nijssen A, Flinterman A, Politiek K, Touwslager WRH, Christoffers WA, Stewart SM, Kamsteeg M, de Graaf M, de Bruin-Weller MS, Schuttelaar MA. Zhang J, et al. Among authors: flinterman a. J Am Acad Dermatol. 2024 Apr 21:S0190-9622(24)00641-8. doi: 10.1016/j.jaad.2024.04.026. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38653344
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek JMPA, Kamsteeg M, Boesjes CM, Romeijn GLE, Loman L, Haeck I, Oosting AJ, de Boer-Brand A, Touwslager WRH, Flinterman A, van Lynden-van Nes AMT, Gostynski AH, de Bruin-Weller MS, Schuttelaar ML. Spekhorst LS, et al. Among authors: flinterman a. JAMA Dermatol. 2022 Sep 1;158(9):1048-1056. doi: 10.1001/jamadermatol.2022.3014. JAMA Dermatol. 2022. PMID: 35947364 Free PMC article.
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Spekhorst LS, Boesjes CM, Loman L, Zuithoff NPA, Bakker DS, Kamphuis E, Kamsteeg M, Haeck IM, Oosting AJ, van Lumig PPM, van Lynden-van Nes AMT, Tupker RA, Flinterman A, Garritsen FM, Touwslager WRH, de Bruin-Weller MS, Schuttelaar MA, de Graaf M. Spekhorst LS, et al. Among authors: flinterman a. Br J Dermatol. 2023 Aug 24;189(3):327-335. doi: 10.1093/bjd/ljad159. Br J Dermatol. 2023. PMID: 37177895
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.
Ariëns LFM, Bakker DS, Spekhorst LS, Van der Schaft J, Thijs JL, Haeck I, Flinterman AE, Kamsteeg M, Schuttelaar MLA, De Bruin-Weller MS. Ariëns LFM, et al. Among authors: flinterman ae. Acta Derm Venereol. 2021 Oct 19;101(10):adv00573. doi: 10.2340/00015555-3886. Acta Derm Venereol. 2021. PMID: 34396421 Free PMC article.
23 results